CETROTIDE (cetrorelix acetate) by Gland Pharma is clinical pharmacology gnrh induces the production and release of luteinizing hormone (lh) and follicle stimulating hormone (fsh) from the gonadotrophic cells of the anterior pituitary. First approved in 2000.
Drug data last refreshed 26m ago · AI intelligence enriched 1mo ago
Cetrotide (cetrorelix acetate) is a GnRH receptor antagonist administered subcutaneously that suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release from the pituitary gland. It is used in controlled ovarian stimulation for assisted reproductive technology to prevent premature ovulation. The drug works by competitive antagonism at GnRH membrane receptors, achieving LH suppression within one to two hours with reversible effects upon discontinuation.
Product approaching loss of exclusivity with moderate competitive pressure (30%) and limited linked career opportunities, suggesting reduced brand team scale.
CLINICAL PHARMACOLOGY GnRH induces the production and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the gonadotrophic cells of the anterior pituitary. Due to a positive estradiol (E2) feedback at midcycle, GnRH liberation is enhanced resulting in an LH-surge. This…
Worked on CETROTIDE at Gland Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)
An Observational Study of Cetrotide® Gonadotropin-releasing Hormone Antagonist (GnRH Antagonist) With GONAL-f® in Assisted Reproductive Technologies (ART)
Working on Cetrotide offers limited growth opportunity as the product approaches loss of exclusivity with minimal active career postings and declining competitive differentiation. Roles are defensive in nature, focused on market maintenance, reimbursement protection, and transition to generic/biosimilar competition rather than market expansion.